8-K
filed May 15, 2023, 7:59 PM ET
ticker FULC
CIK 0001680581
leadership
confidence high
sentiment negative
materiality 0.85
Fulcrum Therapeutics appoints Alex Sapir CEO, reports Q1 net loss of $24.8M, FTX-6058 on clinical hold
Fulcrum Therapeutics, Inc.
- Alex Sapir appointed CEO/President effective July 1, 2023; he will serve as special advisor until then.
- Esther Rajavelu resigned as CFO effective Apr 21, 2023; Robert Gould appointed interim principal financial officer.
- FDA placed FTX-6058 for sickle cell disease on full clinical hold in Feb 2023; active discussions ongoing.
- Phase 3 REACH trial of losmapimod in FSHD enrollment on track to complete in second half of 2023.
- Q1 2023 net loss $24.8M; cash, equivalents, and marketable securities $297.8M; cash runway into mid-2025.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Fulcrum Therapeutics, Inc. reported quarter ended March 31, 2023 results: net income Net loss was $24.8 million.
- Period
- quarter ended March 31, 2023
- Net income
- Net loss was $24.8 million
- Result
- reported results
Exact text from the filing
Collaboration revenue was $0.3 million for the first quarter of 2023 as compared to $2.6 million for the first quarter of 2022.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Fulcrum Therapeutics, Inc. reported quarter ended March 31, 2023 results: net income Net loss was $24.8 million.
- Period
- quarter ended March 31, 2023
- Net income
- Net loss was $24.8 million
- Result
- reported results
Exact text from the filing
Net loss was $24.8 million for the first quarter of 2023 as compared to $25.9 million for the first quarter of 2022.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Alex C. Sapir was appointed as President and Chief Executive Officer at Fulcrum Therapeutics, Inc..
- Action
- appointed
- Role
- President and Chief Executive Officer
Exact text from the filing
On May 11, 2023, the Board also appointed Alex C. Sapir as Fulcrum’s president and chief executive officer, and as a class II director, effective July 1, 2023.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Robert E. Gould was appointed as principal financial officer at Fulcrum Therapeutics, Inc..
- Action
- appointed
- Role
- principal financial officer
Exact text from the filing
On May 11, 2023, in recognition of the duties he is performing and the vacancy in the chief financial officer position, Fulcrum’s board of directors, or the Board, appointed Robert E. Gould, current interim president and chief executive officer, as principal financial officer, with immediate effect.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Robert E. Gould changed role as principal executive officer and principal financial officer at Fulcrum Therapeutics, Inc..
- Action
- succeeded
- Role
- principal executive officer and principal financial officer
Exact text from the filing
Mr. Sapir will succeed Dr. Gould as principal executive officer and as principal financial officer effective July 1, 2023. Dr. Gould will remain on the Board as a class III director.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Alex C. Sapir was appointed as class II director at Fulcrum Therapeutics, Inc..
- Action
- appointed
- Role
- class II director
Exact text from the filing
On May 11, 2023, the Board also appointed Alex C. Sapir as Fulcrum’s president and chief executive officer, and as a class II director, effective July 1, 2023.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.